TSLP

Summary

TSLP (thymic stromal lymphopoietin, HGNC:30743) is a protein-coding gene on chromosome 5q22.1, encoding Thymic stromal lymphopoietin (Q969D9). Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells.

This gene encodes a hemopoietic cytokine proposed to signal through a heterodimeric receptor complex composed of the thymic stromal lymphopoietin receptor and the IL-7R alpha chain. It mainly impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes and enhances the maturation of CD11c(+) dendritic cells. The protein promotes T helper type 2 (TH2) cell responses that are associated with immunity in various inflammatory diseases, including asthma, allergic inflammation and chronic obstructive pulmonary disease. The protein is therefore considered a potential therapeutic target for the treatment of such diseases. In addition, the shorter (predominant) isoform is an antimicrobial protein, displaying antibacterial and antifungal activity against B. cereus, E. coli, E. faecalis, S. mitis, S. epidermidis, and C. albicans. Alternative splicing of this gene results in multiple transcript variants.

Source: NCBI Gene 85480 — RefSeq curated summary.

At a glance

• GWAS associations: 60
• Clinical variants (ClinVar): 31 total
• Druggable target: yes
• MANE Select transcript: NM_033035

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30743
Approved symbol	TSLP
Name	thymic stromal lymphopoietin
Location	5q22.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000145777
Ensembl biotype	protein_coding
OMIM	607003
Entrez	85480

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000344895, ENST00000379706, ENST00000420978

RefSeq mRNA: 2 — MANE Select: NM_033035 NM_033035, NM_138551

CCDS: CCDS4101

Canonical transcript exons

ENST00000344895 — 4 exons

Exon	Start	End
ENSE00001924866	111075946	111078026
ENSE00002211371	111072888	111072932
ENSE00002286480	111073511	111073645
ENSE00002314243	111071713	111072061

Expression profiles

Bgee: expression breadth ubiquitous, 173 present calls, max score 80.54.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.6320 / max 439.8223, expressed in 1034 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
57959	3.7983	924
57960	0.6796	343
57958	0.4197	231
57961	0.2970	149
57957	0.2571	43
203651	0.1772	81
57956	0.0031	1

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	80.54	gold quality
gall bladder	UBERON:0002110	79.34	gold quality
cartilage tissue	UBERON:0002418	78.59	gold quality
right lobe of liver	UBERON:0001114	75.54	gold quality
heart right ventricle	UBERON:0002080	74.97	gold quality
left ventricle myocardium	UBERON:0006566	73.83	gold quality
heart left ventricle	UBERON:0002084	73.64	gold quality
cardiac ventricle	UBERON:0002082	73.34	gold quality
liver	UBERON:0002107	73.31	gold quality
esophagus squamous epithelium	UBERON:0006920	73.23	gold quality
esophagus mucosa	UBERON:0002469	71.66	gold quality
apex of heart	UBERON:0002098	70.98	gold quality
esophagus	UBERON:0001043	69.49	gold quality
heart	UBERON:0000948	69.33	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	68.91	gold quality
urinary bladder	UBERON:0001255	68.83	gold quality
lower esophagus mucosa	UBERON:0035834	68.66	gold quality
prostate gland	UBERON:0002367	67.65	gold quality
right coronary artery	UBERON:0001625	67.51	gold quality
lower esophagus	UBERON:0013473	67.19	gold quality
lower esophagus muscularis layer	UBERON:0035833	67.19	gold quality
right atrium auricular region	UBERON:0006631	66.62	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	66.54	gold quality
cardiac atrium	UBERON:0002081	65.66	gold quality
seminal vesicle	UBERON:0000998	65.13	gold quality
hindlimb stylopod muscle	UBERON:0004252	65.09	gold quality
myocardium	UBERON:0002349	64.57	silver quality
descending thoracic aorta	UBERON:0002345	64.48	gold quality
vermiform appendix	UBERON:0001154	64.46	gold quality
popliteal artery	UBERON:0002250	64.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, BCL11B, HAND2, IRF3, JUN, NFKB1, NFKB, RARG, RELA, VDR

miRNA regulators (miRDB)

114 targeting TSLP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502

Literature-anchored findings (GeneRIF, showing 40)

• This protein is a hemopoietic cytokine that signals through a heterodimeric receptor complex consisting of the human TSLP receptor and the IL-7R alpha-chain. (PMID:11418668)
• Epithelial cell-derived TSLP not only potently activates dendritic cells, but also endows DCs with the ability to polarize naive T cells to produce proallergic Th2 cytokines. (PMID:12055625)
• Data suggest that CD40L-expressing cells may act in combination with thymic stromal lymphopoietin to amplify and sustain pro-allergic responses. (PMID:12707303)
• Reviewer points out that epithelial- and stromal-cell-derived TSLP may represent one of the factors initiating allergic responses, and that it could be a target for a curative therapeutic approach to allergy. (PMID:14999427)
• TSLP is a major regulatory cytokine for CD40 ligand-induced IL-12 production by DCs, and TSLP-activated DCs could promote the persistence of Th2 inflammation even in the presence of IL-12-inducing signals (PMID:15741223)
• Elevated bronchial mucosal expression of TSLP is implicated in asthma pathogenesis; its action is partly through selective development and retention, or recruitment of T helper type 2, not Th1, receptor-bearing cells. (PMID:15944327)
• Review. TSLP influences the outcome of interactions between dendritic cells and CD4+ thymocytes and T cells in many situations. (PMID:16785889)
• inflammatory mediators IL-1beta and TNF-alpha regulate human TSLP gene expression in an NFkappaB-dependent manner (PMID:17213320)
• TSLP, acting upstream of CD4-positive T cell responses, may provide a functional “missing link” between epithelial cells, Langerhans cells, and T-cell-mediated immunity. (PMID:17320941)
• Collectively, these results suggest that TSLP, as a downstream molecule of TNF-alpha, may be involved in the pathophysiology of inflammatory arthritis. (PMID:17416344)
• human airway smooth muscle cells may play a role in chronic obstructive pulmonary disease airway inflammation via TSLP-dependent pathway (PMID:17513456)
• Human CD4-positive T cells are direct targets for thymic stromal lymphopoietin (TSLP). (PMID:17513717)
• IL-25 produced by innate effector eosinophils and basophils may augment the allergic inflammation by enhancing the maintenance and functions of TSLP-DC activated adaptive Th2 memory cells (PMID:17635955)
• Master switch of allergic inflammation at epithelial cell and dendritic cell interface. Link between TSLP and atopic dermatitis and asthma. Review. (PMID:17666213)
• RSV F protein stimulates TSLP expression in human bronchial epithelial cells mediated partially by p38 and JNK signal pathways. (PMID:17959543)
• Dendritic cells exposed to diesel exhaust particle-treated human bronchial epithelial cells induced Th2 polarization in a thymic stromal lymphopoietin-dependent manner. (PMID:18049884)
• OX40 ligand (OX40L) is a critical in vivo mediator of TSLP-mediated Th2 responses. (PMID:18060034)
• In a sex-stratified analysis, there was significant evidence of linkage to IgE to cockroach on chromosome 5q23; in female subjects,the T allele of single-nucleotide polymorphism rs2289276 in TSLP was associated with reductions in IgE to cockroach (PMID:18244952)
• REVIEW: effect of the functional versatility of hTSLP-activated DCs (hTSLP-DCs) on T cells (PMID:18445339)
• There is distinct airways expression of TSLP and chemokines which preferentially attract T helper (Th) type 1- and Th2-type T cells, and influx of T cells bearing their receptors in asthma and chronic obstructive pulmonary disease. (PMID:18684970)
• TSLP was detected in all samples and the mRNA and protein expression of TSLP is increased significantly in allergic rhinitis nasal mucosa. TSLP production is tightly correlated with IL-4 and severity of allergic rhinitis. (PMID:18720075)
• Data demonstrate that lysophosphatidic acid stimulates thymic stromal lymphopoietin and CCL20 expression in bronchial epithelial cells via CARMA3-mediated NF-kappaB activation. (PMID:18757306)
• A TSLP-driven mouse model of inflammation exhibits many characteristics of human atopic dermatitis, including infiltrate of CD4-positive cells, eosinophils, mast cells; production of Th2 cytokines; and class switching to produce immunoglobulin E. (PMID:18768889)
• Data suggest that functional genetic polymorphism of the TSLP gene appears to contribute to Th2-polarized immunity through higher TSLP production by bronchial epithelial cells in response to viral respiratory infections. (PMID:18787178)
• expression correlates with presence/ severity of lesions in atopic dermatitis patients (PMID:18802341)
• high expression in lungs of patients with asthma; undetectable expression in epithelial cells of patients with Crohn disease (PMID:18802347)
• expression level is increased in patients with asthma (PMID:18802348)
• Inhibition of NF-kappaB-mediated TSLP expression by retinoid X receptor (PMID:18832669)
• thymic stromal lymphopoietin (TSLP) and human DCs plays an essential role in evoking inflammatory Th2 responses in allergy through OX40 ligand expression on DCs. (PMID:18832690)
• Study of pathways engaged in transgenic model of thymic stromal lymphopoietin-driven airway inflammation demonstrates that simultaneous blockade of interleukin (IL)-13 and IL-4 can reverse established asthma-like chronic airway disease. (PMID:18941246)
• Through DC activation, human TSLP and TLR3 ligands promote differentiation of Th17 cells with the central memory T cell phenotype under Th2-polarizing conditions. (PMID:19055649)
• Cytokine milieu modulates release of thymic stromal lymphopoietin from human keratinocytes stimulated with double-stranded RNA. (PMID:19056108)
• The pathogenic phenotype that develops in the transgenic mouse lung in response to TSLP is governed almost exclusively by a TSLP-facilitated adaptive response directed against foreign antigen. (PMID:19155513)
• mast cells are able to store TSLP intracellularly and to produce TSLP following aggregation of FcepsilonRI in the presence of IL-4 (PMID:19164348)
• The data suggest that TSLP plays a role in augmenting, through DC recruitment and activation, the development of Th2-type T cells in allergic inflammation. (PMID:19187393)
• Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells. (PMID:19348931)
• A genetic variant in the region of the thymic stromal lymphopoietin gene is associated with the phenotypes of asthma and airway hyperresponsiveness. (PMID:19539984)
• C allele at the TSLP -847C>T polymorphism may increase susceptibility to generalized vitiligo through decreasing TSLP mRNA expression levels. (PMID:19555430)
• TSLP expression is induced in airway epithelial cells by exposure to allergen-derived proteases and PAR-2 is involved in the process. (PMID:19561109)
• The TSLP protein produced in conjunctival epithelial cells plays a role in severe ocular allergy through the activation of dendritic cells and mast cells in synergy with other cytokines (PMID:19741251)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Tslp	ENSMUSG00000024379
rattus_norvegicus	Tslp	ENSRNOG00000058856

Protein

Protein identifiers

Thymic stromal lymphopoietin — Q969D9 (reviewed: Q969D9)

All UniProt accessions (2): A0A0C4DG43, Q969D9

UniProt curated annotations — full annotation on UniProt →

Function. Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c(+) dendritic cells. Can induce allergic inflammation by directly activating mast cells. May act as an antimicrobial peptide in the oral cavity and on the skin.

Subunit / interactions. Interacts with a receptor composed of CRLF2 and IL7R. Binding of TSLP to CRLF2/TSLPR is a mechanistic prerequisite for recruitment of IL7R to the high-affinity ternary complex.

Subcellular location. Secreted.

Tissue specificity. Isoform 1 is expressed in a number of tissues including heart, liver and prostate. Isoform 2 is the predominant form in keratinocytes of oral mucosa, skin and in salivary glands. It is secreted into saliva.

Induction. Released by primary epithelial cells in response to certain microbial products, physical injury, or inflammatory cytokines.

Isoforms (2)

UniProt ID	Names	Canonical?
Q969D9-1	1, lfTSLP	yes
Q969D9-2	2, sfTSLP

RefSeq proteins (2): NP_149024, NP_612561 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029189	TSLP	Family
IPR038329	TSLP_sf	Homologous_superfamily

Pfam: PF15216

UniProt features (16 total): helix 7, disulfide bond 3, glycosylation site 2, signal peptide 1, chain 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
8QFZ	X-RAY DIFFRACTION	1.65
5J13	X-RAY DIFFRACTION	2.3
5J11	X-RAY DIFFRACTION	2.56
8ZEU	ELECTRON MICROSCOPY	3.39
5J12	X-RAY DIFFRACTION	3.55

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q969D9-F1	78.95	0.47

Antibody-complex structures (SAbDab): 2 — 5J13, 8ZEU

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3): 34–110, 69–75, 90–137

Glycosylation sites (2): 64, 119

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1266695	Interleukin-7 signaling

MSigDB gene sets: 192 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, CREL_01, BENPORATH_ES_WITH_H3K27ME3, GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, MODULE_255, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, MENSE_HYPOXIA_UP, MODULE_317, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, GOBP_CELL_SURFACE_RECEPTOR_SIGNALING_PATHWAY_VIA_JAK_STAT, NFKB_Q6, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, MARTINEZ_RB1_TARGETS_UP

GO Biological Process (20): positive regulation of cytokine-mediated signaling pathway (GO:0001961), cell surface receptor signaling pathway via JAK-STAT (GO:0007259), positive regulation of cell population proliferation (GO:0008284), cytokine-mediated signaling pathway (GO:0019221), positive regulation of chemokine production (GO:0032722), positive regulation of interleukin-10 production (GO:0032733), positive regulation of interleukin-13 production (GO:0032736), positive regulation of interleukin-5 production (GO:0032754), positive regulation of interleukin-6 production (GO:0032755), positive regulation of mast cell activation (GO:0033005), interleukin-7-mediated signaling pathway (GO:0038111), negative regulation of apoptotic process (GO:0043066), positive regulation of inflammatory response (GO:0050729), defense response to Gram-negative bacterium (GO:0050829), defense response to fungus (GO:0050832), antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844), positive regulation of chemokine (C-C motif) ligand 1 production (GO:0071654), positive regulation of granulocyte colony-stimulating factor production (GO:0071657), positive regulation of receptor signaling pathway via STAT (GO:1904894), signal transduction (GO:0007165)

GO Molecular Function (2): cytokine activity (GO:0005125), interleukin-7 receptor binding (GO:0005139)

GO Cellular Component (2): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Interleukins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of cytokine production	5
positive regulation of signal transduction	2
cytokine-mediated signaling pathway	2
cell surface receptor signaling pathway via STAT	2
regulation of cytokine-mediated signaling pathway	1
positive regulation of response to cytokine stimulus	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
chemokine production	1
regulation of chemokine production	1
interleukin-10 production	1
regulation of interleukin-10 production	1
interleukin-13 production	1
regulation of interleukin-13 production	1
interleukin-5 production	1
regulation of interleukin-5 production	1
interleukin-6 production	1
regulation of interleukin-6 production	1
positive regulation of leukocyte activation	1
regulation of mast cell activation	1
mast cell activation	1
cellular response to interleukin-7	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
inflammatory response	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1
regulation of inflammatory response	1
defense response to bacterium	1
defense response	1
response to fungus	1
antimicrobial humoral response	1
positive regulation of chemokine production	1
chemokine (C-C motif) ligand 1 production	1
regulation of chemokine (C-C motif) ligand 1 production	1
granulocyte colony-stimulating factor production	1

Protein interactions and networks

STRING

1584 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TSLP	CRLF2	Q9HC73	999
TSLP	IL7R	P16871	997
TSLP	IL33	O95760	925
TSLP	IL13	P35225	878
TSLP	IL7	P13232	867
TSLP	KLK11	Q9UBX7	865
TSLP	IL4	P05112	862
TSLP	IL5	P05113	859
TSLP	CCL17	Q92583	854
TSLP	IL17A	Q16552	828
TSLP	IL1RL1	Q01638	823
TSLP	TNFSF4	P23510	818
TSLP	IL17RB	Q9NRM6	802
TSLP	IFNG	P01579	796
TSLP	CCL22	O00626	795

IntAct

3 interactions, top by confidence:

A	B	Type	Score
TSLP	PRNP	psi-mi:“MI:0407”(direct interaction)	0.000
TSLP	IKBKG	psi-mi:“MI:0407”(direct interaction)	0.000

BioGRID (11): TSLP (Reconstituted Complex), TSLP (Biochemical Activity), TSLP (Co-fractionation), TSLP (Co-fractionation), TSLP (Co-fractionation), TSLP (Co-fractionation), TSLP (Co-fractionation), WASF1 (Co-fractionation), TSLP (Reconstituted Complex), TSLP (Reconstituted Complex), APP (Reconstituted Complex)

ESM2 similar proteins: A0A1B0GVD1, A0A3B7TNM4, A0A903V9Z8, A8R0V4, B2ZCQ1, B2ZCQ2, B2ZCQ3, C6EN00, I6LJ77, O14278, O42654, O92277, O94245, P03319, P03320, P03321, P09308, P0C9K3, P0DOE1, P10260, P10261, P13781, P20403, P26706, P33467, P52526, P52536, P53074, P56528, P60505, P60506, Q00033, Q01226, Q06707, Q62574, Q64244, Q65186, Q66672, Q69553, Q6R7F5

Diamond homologs: Q969D9, Q9JIE6

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
TSLP	up-regulates	CRLF2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

31 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

622 predictions. Top by Δscore:

Variant	Effect	Δscore
5:111072057:GTGGG:G	donor_gain	1.0000
5:111072883:TCCA:T	acceptor_loss	1.0000
5:111072884:CCAG:C	acceptor_loss	1.0000
5:111072885:CAGA:C	acceptor_loss	1.0000
5:111072886:A:AG	acceptor_gain	1.0000
5:111072886:A:C	acceptor_loss	1.0000
5:111072887:G:GC	acceptor_gain	1.0000
5:111072887:G:T	acceptor_loss	1.0000
5:111072887:GACC:G	acceptor_gain	1.0000
5:111072929:TCGGG:T	donor_loss	1.0000
5:111072931:GG:G	donor_gain	1.0000
5:111072931:GGGT:G	donor_loss	1.0000
5:111072932:GG:G	donor_gain	1.0000
5:111072932:GGTG:G	donor_loss	1.0000
5:111072933:G:GA	donor_loss	1.0000
5:111072933:G:GG	donor_gain	1.0000
5:111072934:TGA:T	donor_loss	1.0000
5:111072935:GAGTA:G	donor_loss	1.0000
5:111072936:AG:A	donor_loss	1.0000
5:111073467:T:TA	acceptor_gain	1.0000
5:111073486:C:A	acceptor_gain	1.0000
5:111073489:A:AG	acceptor_gain	1.0000
5:111073490:A:G	acceptor_gain	1.0000
5:111073492:C:G	acceptor_gain	1.0000
5:111073503:A:AG	acceptor_gain	1.0000
5:111073504:T:G	acceptor_gain	1.0000
5:111073642:TCAGG:T	donor_loss	1.0000
5:111073643:CAGGT:C	donor_loss	1.0000
5:111073644:AGG:A	donor_loss	1.0000
5:111073645:GGT:G	donor_loss	1.0000

AlphaMissense

1039 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:111076038:G:C	W148C	0.983
5:111076038:G:T	W148C	0.983
5:111076036:T:A	W148R	0.976
5:111076036:T:C	W148R	0.976
5:111071981:T:C	F31L	0.973
5:111071983:C:A	F31L	0.973
5:111071983:C:G	F31L	0.973
5:111073622:T:A	C110S	0.973
5:111073623:G:C	C110S	0.973
5:111073587:T:G	F98C	0.971
5:111073530:T:C	I79T	0.966
5:111073622:T:C	C110R	0.965
5:111073586:T:C	F98L	0.964
5:111073588:C:A	F98L	0.964
5:111073588:C:G	F98L	0.964
5:111076025:T:C	L144S	0.960
5:111073624:C:G	C110W	0.958
5:111073517:T:A	C75S	0.956
5:111073518:G:C	C75S	0.956
5:111072042:T:C	L51P	0.952
5:111073530:T:G	I79S	0.951
5:111071990:T:A	C34S	0.945
5:111071991:G:C	C34S	0.945
5:111073521:T:C	L76P	0.945
5:111073521:T:A	L76H	0.944
5:111071982:T:G	F31C	0.941
5:111073517:T:C	C75R	0.941
5:111073623:G:A	C110Y	0.940
5:111073519:C:G	C75W	0.938
5:111071996:T:C	F36L	0.937

dbSNP variants (sampled 300 via entrez): RS1000002184 (5:111073714 C>T), RS1000156319 (5:111068776 A>G), RS1000829748 (5:111078461 G>A,T), RS1001005242 (5:111075043 G>A), RS1001110038 (5:111070079 A>G,T), RS1001220324 (5:111073389 C>G,T), RS1001562729 (5:111069905 T>C), RS1001577515 (5:111068165 A>T), RS1001582054 (5:111070258 T>C), RS1001586685 (5:111075571 T>C,G), RS1001691553 (5:111075123 T>A), RS1001917545 (5:111069025 G>A), RS1002143686 (5:111075332 A>G), RS1002177100 (5:111069348 CATG>C), RS1002323577 (5:111074367 G>C)

Disease associations

OMIM: gene MIM:607003 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

60 associations (top):

Study	Trait	p-value
GCST000339_5	Eosinophil count	1.000000e-06
GCST001182_2	Asthma	1.000000e-14
GCST001183_3	Asthma	1.000000e-16
GCST001310_8	Allergic rhinitis	5.000000e-06
GCST002083_18	Self-reported allergy	2.000000e-20
GCST002084_11	Allergic sensitization	5.000000e-14
GCST002322_6	Asthma and hay fever	1.000000e-09
GCST002527_4	Eosinophilic esophagitis	2.000000e-08
GCST002697_2	Eosinophilic esophagitis	4.000000e-14
GCST003831_44	Asthma	4.000000e-07
GCST003987_4	Asthma	3.000000e-31
GCST004600_156	Eosinophil percentage of white cells	4.000000e-21
GCST004606_121	Eosinophil count	2.000000e-22
GCST004617_101	Eosinophil percentage of granulocytes	2.000000e-18
GCST004623_6	Neutrophil percentage of granulocytes	3.000000e-15
GCST005038_123	Allergic disease (asthma, hay fever or eczema)	1.000000e-22
GCST005038_124	Allergic disease (asthma, hay fever or eczema)	2.000000e-31
GCST005038_19	Allergic disease (asthma, hay fever or eczema)	6.000000e-29
GCST005212_40	Asthma	9.000000e-26
GCST006862_11	Asthma	2.000000e-25
GCST006862_22	Asthma	8.000000e-11
GCST006911_25	Asthma (moderate or severe)	2.000000e-22
GCST007443_2	Nasal polyps	4.000000e-29
GCST007562_1	Asthma	2.000000e-20
GCST007563_10	Allergic disease (asthma, hay fever or eczema)	5.000000e-20
GCST007564_29	Asthma or allergic disease (pleiotropy)	4.000000e-21
GCST007797_2	Asthma onset (childhood vs adult)	5.000000e-15
GCST007797_26	Asthma onset (childhood vs adult)	8.000000e-10
GCST007798_70	Asthma	2.000000e-29
GCST007798_71	Asthma	2.000000e-29

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0004842	eosinophil count
EFO:0005298	allergic sensitization measurement
EFO:0007991	eosinophil percentage of leukocytes
EFO:0007996	eosinophil percentage of granulocytes
EFO:0007994	neutrophil percentage of granulocytes
EFO:0004847	age at onset
EFO:1002011	adult onset asthma
EFO:0009941	Inhalant adrenergic use measurement
EFO:0009942	Glucocorticoid use measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712931 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

50 potent at pChembl≥5 of 50 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.70	Kd	2	nM	CHEMBL5594472
8.52	Kd	3	nM	CHEMBL5568693
8.52	Kd	3	nM	CHEMBL5563474
8.52	Kd	3	nM	CHEMBL5573652
8.40	Kd	4	nM	CHEMBL5566614
8.22	Kd	6	nM	CHEMBL5595593
8.22	Kd	6	nM	CHEMBL5574722
8.22	Kd	6	nM	CHEMBL5569104
8.22	Kd	6	nM	CHEMBL5572108
8.05	Kd	9	nM	CHEMBL5583600
7.89	Kd	13	nM	CHEMBL5593210
7.89	Kd	13	nM	CHEMBL5571424
7.85	Kd	14	nM	CHEMBL5542413
7.85	Kd	14	nM	CHEMBL5564500
7.70	Kd	20	nM	CHEMBL5574606
7.54	Kd	29	nM	CHEMBL5571446
7.51	Kd	31	nM	CHEMBL5589795
7.48	Kd	33	nM	CHEMBL5574168
7.48	Kd	33	nM	CHEMBL5589702
7.48	Kd	33	nM	CHEMBL5575601
7.44	Kd	36	nM	CHEMBL5573129
7.43	Kd	37	nM	CHEMBL5566682
7.37	Kd	43	nM	CHEMBL5594799
7.32	Kd	48	nM	CHEMBL5571168
7.28	Kd	52	nM	CHEMBL5564182
7.16	Kd	70	nM	CHEMBL5569889
7.12	Kd	75	nM	CHEMBL5572561
7.11	Kd	77	nM	CHEMBL5572417
7.09	Kd	82	nM	CHEMBL5573827
7.01	Kd	98	nM	CHEMBL5572866
7.01	Kd	97	nM	CHEMBL5571015
7.00	Kd	100	nM	CHEMBL5570697
6.96	Kd	110	nM	CHEMBL5563347
6.96	Kd	110	nM	CHEMBL5572390
6.89	Kd	130	nM	CHEMBL5563312
6.89	Kd	130	nM	CHEMBL5567065
6.80	Kd	160	nM	CHEMBL5569905
6.72	Kd	190	nM	CHEMBL5569814
6.70	Kd	200	nM	CHEMBL5579715
6.68	Kd	210	nM	CHEMBL5575035
6.66	Kd	220	nM	CHEMBL5575721
6.64	Kd	230	nM	CHEMBL5593764
6.58	Kd	260	nM	CHEMBL5570404
6.54	Kd	290	nM	CHEMBL5567424
6.39	Kd	410	nM	CHEMBL5563591
6.33	Kd	470	nM	CHEMBL5572000
6.18	Kd	664	nM	CHEMBL5567113
6.05	Kd	900	nM	CHEMBL5564963
5.96	Kd	1100	nM	CHEMBL5567325
5.82	Kd	1500	nM	CHEMBL5572731

PubChem BioAssay actives

50 with measured affinity, of 114 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12,21-bis(3-amino-3-oxopropyl)-42-carbamoyl-39-[(3-chloro-4-fluorophenyl)methyl]-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-15,30-bis[(1-methylindol-3-yl)methyl]-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0020	uM
3-[(9R,12S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0030	uM
3-[(9R,12S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-42-carbamoyl-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-15,30-bis[(1-methylindol-3-yl)methyl]-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0030	uM
2-[(9R,12S,18S,21S,27R,30S,33S,39S,42R)-9-acetamido-21-(3-amino-3-oxopropyl)-42-carbamoyl-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-11,12,23-trimethyl-15,30-bis[(1-methylindol-3-yl)methyl]-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0030	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(3-chloro-4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0040	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0060	uM
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12,21-bis(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0060	uM
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-21-(3-amino-3-oxopropyl)-42-carbamoyl-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-11,12-dimethyl-15,30-bis[(1-methylindol-3-yl)methyl]-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0060	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(4-chlorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0060	uM
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12,21-bis(3-amino-3-oxopropyl)-42-carbamoyl-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0090	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-42-carbamoyl-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-11,12-dimethyl-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0130	uM
2-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-21-(3-amino-3-oxopropyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-18-(2,2-dimethylpropyl)-39-[(4-fluorophenyl)methyl]-11,12-dimethyl-30-[(1-methylindol-3-yl)methyl]-15-(naphthalen-1-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-24-yl]acetic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0130	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-24-(carboxymethyl)-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0140	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(3-chlorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0140	uM
3-[(9R,12S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-42-carbamoyl-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-39-[(4-fluorophenyl)methyl]-30-(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-15-(naphthalen-1-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0200	uM
(3S)-4-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-[[2-[[(2S)-2-[[(2S)-2-[[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-12-(3-amino-3-oxopropyl)-9-[[(2S)-2-aminopropanoyl]amino]-39-benzyl-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontane-42-carbonyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-4-oxobutanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0290	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(2,2-dimethylpropyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0310	uM
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[(2-aminoacetyl)amino]-3-hydroxybutanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-[[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-9-yl]amino]-5-oxopentanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0330	uM
(9R,12R,15S,18S,21S,24R,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-39-[(4-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontane-42-carboxylic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0330	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-39-(naphthalen-1-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0330	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-39-[(4-fluorophenyl)methyl]-30-(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-15-(naphthalen-1-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0360	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-39-(naphthalen-2-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0370	uM
(3S)-4-amino-3-[[(2S)-2-[[(2S)-1-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-12-(3-amino-3-oxopropyl)-9-[[(2S)-2-aminopropanoyl]amino]-39-benzyl-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontane-42-carbonyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0430	uM
(4S)-4-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-21-(2-carboxyethyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-9-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0480	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S,52Z)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,60-tetradecaoxo-9,21,57-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.6.515,38.113,17]henhexacont-52-en-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0520	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(cyclopentylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0700	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-12-(3-amino-3-oxopropyl)-9-[[(2S)-2-aminopropanoyl]amino]-39-benzyl-33-(3-carbamimidamidopropyl)-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0750	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,60-tetradecaoxo-9,21,57-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.6.515,38.113,17]henhexacontan-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0770	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,62-tetradecaoxo-9,21,59-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.8.515,38.113,17]trihexacontan-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0820	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S,52E)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,60-tetradecaoxo-9,21,57-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.6.515,38.113,17]henhexacont-52-en-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0970	uM
3-[(9R,12S,15S,18S,21S,24S,27S,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.0980	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(cyclopropylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1000	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-(cyclohexylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1100	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-42-carbamoyl-24-(carboxymethyl)-33-[3-[(N,N-dimethylcarbamimidoyl)amino]propyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1100	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-18-propyl-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1300	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-39-[(4-methylphenyl)methyl]-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1300	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-42-carbamoyl-33-[3-(carbamoylamino)propyl]-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1600	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(2-fluorophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.1900	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-18-(2,2,2-trifluoroethyl)-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2000	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(4-carbamimidamidobutyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2100	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-(cyclohexylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2200	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-24-(2-amino-2-oxoethyl)-42-[[(2S)-1-amino-1-oxopropan-2-yl]carbamoyl]-9-[[(2S)-2-aminopropanoyl]amino]-39-benzyl-33-(3-carbamimidamidopropyl)-12-(1H-imidazol-4-ylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2300	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-39-[(4-cyanophenyl)methyl]-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2600	uM
3-[(9R,12S,15S,18S,21S,24S,27S,30S,33S,39S,42R)-9-acetamido-24-(2-amino-2-oxoethyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-12-(1H-imidazol-4-ylmethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.2900	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-39-(thiophen-3-ylmethyl)-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.4100	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(2-carbamimidamidoethyl)-42-carbamoyl-24-(carboxymethyl)-15,30-bis(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.4700	uM
3-[(1S,4S,7R,23R,26S,32S,35S,38R,41S,44S,47S)-7-acetamido-4-(3-amino-3-oxopropyl)-23-carbamoyl-41-(carboxymethyl)-26-[(4-fluorophenyl)methyl]-35-(1H-indol-3-ylmethyl)-47-(2-methylpropyl)-3,6,12,18,25,28,31,34,37,40,43,46,49,61-tetradecaoxo-9,21,58-trithia-2,5,13,15,17,24,27,30,33,36,39,42,45,48-tetradecazatetracyclo[30.17.7.515,38.113,17]dohexacontan-44-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.6640	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-15,33-bis(but-3-enyl)-42-carbamoyl-24-(carboxymethyl)-39-[(4-fluorophenyl)methyl]-30-(1H-indol-3-ylmethyl)-18-(2-methylpropyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	0.9000	uM
3-[(9R,12S,15S,18S,21S,24S,27R,31S,34S,40S,43R)-9-acetamido-12-(3-amino-3-oxopropyl)-40-benzyl-43-carbamoyl-24-(carboxymethyl)-15,31-bis(1H-indol-3-ylmethyl)-34-methyl-18-(2-methylpropyl)-4,10,13,16,19,22,25,29,32,35,38,41,48,51-tetradecaoxo-7,45,54-trithia-1,3,11,14,17,20,23,26,30,33,36,39,42,49-tetradecazatricyclo[25.23.4.13,49]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	1.1000	uM
3-[(9R,12S,15S,18S,21S,24S,27R,30S,33S,39S,42R)-9-acetamido-12-(3-amino-3-oxopropyl)-39-benzyl-33-(3-carbamimidamidopropyl)-42-carbamoyl-24-(carboxymethyl)-18-ethyl-15,30-bis(1H-indol-3-ylmethyl)-4,10,13,16,19,22,25,28,31,34,37,40,47,50-tetradecaoxo-7,44,53-trithia-1,3,11,14,17,20,23,26,29,32,35,38,41,48-tetradecazatricyclo[25.22.5.13,48]pentapentacontan-21-yl]propanoic acid	2099717: Binding affinity to TEV cleavable N-terminal 6xHN/ C-terminal Avi-tagged biotinylated human TSLP (29 to 159 residues) transfected in human Expi293F cells assessed as dissociation constant by SPR analysis	kd	1.5000	uM

CTD chemical–gene interactions

90 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Particulate Matter	decreases reaction, increases expression, decreases expression, increases abundance, increases secretion (+1 more)	9
Valproic Acid	affects cotreatment, increases expression, affects expression	7
bisphenol A	increases methylation, affects expression, decreases expression, increases expression	3
Acetaminophen	affects cotreatment, increases expression, decreases expression	3
Vehicle Emissions	affects reaction, increases secretion, decreases reaction, increases expression	3
Tetradecanoylphorbol Acetate	decreases reaction, increases expression, increases secretion, affects cotreatment	3
sodium arsenite	decreases expression, increases expression	2
Acetylcysteine	decreases reaction, increases expression	2
Air Pollutants	increases abundance, increases expression, decreases expression	2
Benzo(a)pyrene	increases expression, affects methylation	2
Estradiol	affects cotreatment, decreases expression, increases expression, increases reaction	2
Lipopolysaccharides	decreases reaction, increases secretion, increases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Poly I-C	increases expression, increases reaction, affects cotreatment, decreases reaction	2
Cyclosporine	increases expression	2
Aflatoxin B1	affects expression, decreases methylation, increases expression	2
Glupearl 19S	decreases reaction, increases expression	1
helenalin	decreases reaction, increases expression, affects cotreatment	1
parthenolide	decreases reaction, increases expression	1
naringin	affects cotreatment, decreases reaction, increases expression	1
kaempferol	decreases reaction, increases expression, increases secretion	1
chelex	decreases reaction, increases secretion	1
ethyl-p-hydroxybenzoate	increases expression	1
arsenite	increases methylation	1
mono-(2-ethylhexyl)phthalate	decreases methylation, increases abundance	1
pyrrolidine dithiocarbamic acid	decreases reaction, increases expression	1
nickel chloride	increases reaction, increases expression	1
butylbenzyl phthalate	decreases methylation, increases abundance	1
ceric oxide	affects cotreatment, increases expression	1
hydroquinone	increases expression	1

ChEMBL screening assays

12 unique, capped per target: 12 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4047224	Binding	Inhibition of human N-terminal flag-tagged TSLP/human C-terminal octa histidine-tagged TSLPR interaction at 0.1 mM after 16 hrs by ELISA based spectrophotometric analysis	Synthesis and biological evaluation of peptide-derived TSLP inhibitors. — Bioorg Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D9V4	Ubigene HEK293 TSLP KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.